Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 427 entries
View as:

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00689936 Org: User:
Start: 08/21/08 End: 07/14/16 Due: 07/14/17

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT04560738 Org: User:
Start: 10/15/20 End: 05/13/21 Due: 05/13/22

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00424047 Org: User:
Start: 01/01/03 End: 11/12/13 Due: 11/12/14

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03135509 Org: User:
Start: 05/24/17 End: 06/28/17 Due: 06/28/18

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Phase: N/A Priority: Normal
NCT ID: NCT04991935 Org: User:
Start: 09/14/21 End: 09/29/26 Due: 09/29/27

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02103062 Org: User:
Start: 05/05/14 End: 01/09/15 Due: 01/09/16

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02773030 Org: User:
Start: 10/14/16 End: 02/06/28 Due: 02/06/29

A Phase 1 QT Study in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01986894 Org: User:
Start: 10/18/13 End: 12/02/13 Due: 12/02/14

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Phase: N/A Priority: Normal
NCT ID: NCT03098589 Org: User:
Start: 05/30/17 End: 09/18/20 Due: 09/18/21

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00102687 Org: User:
Start: 01/01/05 End: 08/01/08 Due: 08/01/09

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Phase: N/A Priority: Normal
NCT ID: NCT02098473 Org: User:
Start: 08/31/14 End: 01/30/17 Due: 01/30/18

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00179673 Org: User:
Start: 06/30/05 End: 04/30/08 Due: 04/30/09

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00657488 Org: User:
Start: 12/01/01 End: 04/01/06 Due: 04/01/07

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT00652626 Org: User:
Start: 11/01/08 End: 07/01/12 Due: 07/01/13

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03361748 Org: User:
Start: 12/13/17 End: 12/20/23 Due: 12/20/24

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Phase: N/A Priority: Normal
NCT ID: NCT01353664 Org: User:
Start: 05/01/11 End: 09/05/12 Due: 09/05/13

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT02281084 Org: User:
Start: 07/06/15 End: 09/14/23 Due: 09/14/24

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04882163 Org: User:
Start: 10/10/21 End: 04/07/29 Due: 04/07/30

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Phase: N/A Priority: Normal
NCT ID: NCT01311687 Org: User:
Start: 03/11/11 End: 08/29/17 Due: 08/29/18

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04324840 Org: User:
Start: 07/10/20 End: 07/09/24 Due: 07/09/25

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04428788 Org: User:
Start: 06/22/20 End: 12/27/26 Due: 12/27/27

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02223052 Org: User:
Start: 10/27/14 End: 12/18/18 Due: 12/18/19

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Phase: N/A Priority: Normal
NCT ID: NCT01353625 Org: User:
Start: 04/25/11 End: 03/12/21 Due: 03/12/22

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05028634 Org: User:
Start: 11/11/21 End: 11/15/23 Due: 11/15/24

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Phase: N/A Priority: Normal
NCT ID: NCT02797015 Org: User:
Start: 06/23/16 End: 10/20/17 Due: 10/20/18